MedTrace Logo

The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology

NCT04694482 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2023-09-07

Study results available
· View outcomes & findings →

Summary

The outbreak of the SARS-CoV-2 pandemic may be considered a traumatic phenomenon.

In a sample of subjects suffering from different psychiatric disorders, psychopathological status and Post-Traumatic Stress Disorder (PTSD) symptoms over time are assessed using specific psychometric scales. In a sample of healthy controls PTSD symptoms are evaluated by Impact of Event Scale Revised (IES-R) and compared to patients' scores.

We hypothesize that a significant number of psychiatric outpatients have experienced a clinical psychopathological worsening and a greater prevalence of PTSD symptoms compared to the general population. The study of the potential psychopathological changes could represent a useful contribution to deepen the understanding of psychological consequences of the pandemic.

Conditions

  • Psychosis;Schizophrenic
  • Personality Disorders
  • Mood Disorders
  • Anxiety Disorders
  • Post Traumatic Stress Disorder

Interventions

OTHER

Psychometric scale administration

PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups

Sponsors & Collaborators

  • Azienda Ospedaliera San Gerardo di Monza

    collaborator OTHER

  • University of Milano Bicocca

    lead OTHER

Principal Investigators

  • Fabrizia Colmegna, MD · ASST Monza

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-12
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04694482 on ClinicalTrials.gov